State Street Corp Raises Stake in LENZ Therapeutics, Inc. (NASDAQ:LENZ)

State Street Corp grew its holdings in shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ) by 18.7% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 289,154 shares of the company’s stock after acquiring an additional 45,600 shares during the quarter. State Street Corp owned 1.05% of LENZ Therapeutics worth $6,865,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in LENZ. Bank of New York Mellon Corp grew its holdings in shares of LENZ Therapeutics by 255.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 39,737 shares of the company’s stock valued at $687,000 after purchasing an additional 28,556 shares during the last quarter. Rhumbline Advisers boosted its position in LENZ Therapeutics by 265.6% during the second quarter. Rhumbline Advisers now owns 16,812 shares of the company’s stock valued at $291,000 after buying an additional 12,214 shares during the period. BBR Partners LLC bought a new position in shares of LENZ Therapeutics during the second quarter valued at about $346,000. Dimensional Fund Advisors LP grew its stake in shares of LENZ Therapeutics by 58.0% during the second quarter. Dimensional Fund Advisors LP now owns 37,190 shares of the company’s stock valued at $644,000 after buying an additional 13,653 shares during the last quarter. Finally, Renaissance Technologies LLC increased its holdings in shares of LENZ Therapeutics by 28.4% in the second quarter. Renaissance Technologies LLC now owns 60,166 shares of the company’s stock worth $1,040,000 after buying an additional 13,300 shares during the period. 54.32% of the stock is currently owned by institutional investors.

LENZ Therapeutics Trading Down 2.2 %

NASDAQ LENZ opened at $31.32 on Friday. LENZ Therapeutics, Inc. has a fifty-two week low of $14.42 and a fifty-two week high of $38.93. The stock has a 50 day simple moving average of $32.25 and a two-hundred day simple moving average of $25.53.

LENZ Therapeutics (NASDAQ:LENZ) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.09. During the same period in the previous year, the business posted ($1.33) earnings per share. On average, sell-side analysts expect that LENZ Therapeutics, Inc. will post -2.09 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages recently weighed in on LENZ. Raymond James started coverage on LENZ Therapeutics in a report on Friday, September 27th. They set an “outperform” rating and a $37.00 target price for the company. HC Wainwright reissued a “buy” rating and set a $38.00 price objective on shares of LENZ Therapeutics in a research note on Thursday, November 7th. Finally, William Blair raised shares of LENZ Therapeutics to a “strong-buy” rating in a research note on Friday, August 30th. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $35.40.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.